DNA vaccines: precision tools for activating effective immunity against cancer
DNA vaccines: precision tools for activating effective immunity against cancer
DNA vaccination has suddenly become a favoured strategy for inducing immunity. The molecular precision offered by gene-based vaccines, together with the facility to include additional genes to direct and amplify immunity, has always been attractive. However, the apparent failure to translate operational success in preclinical models to the clinic, for reasons that are now rather obvious, reduced initial enthusiasm. Recently, novel delivery systems, especially electroporation, have overcome this translational block. Here, we assess the development, current performance and potential of DNA vaccines for the treatment of cancer
plasmid dna, immunity, phase-i, cancer, gene, protective immunity, minor histocompatibility antigens, development, genes, electroporation in-vivo, tumor-antigen, treatment, models, vaccine, b surface-antigen, time, dna, model, refractory prostate-cancer, cd8(+) t-cells, dendritic cells
108-120
Rice, J.
d58d4fcd-8dc0-4599-bf96-62323d579227
Ottensmeier, C.H.
42b8a398-baac-4843-a3d6-056225675797
Stevenson, F.K.
ba803747-c0ac-409f-a9c2-b61fde009f8c
2008
Rice, J.
d58d4fcd-8dc0-4599-bf96-62323d579227
Ottensmeier, C.H.
42b8a398-baac-4843-a3d6-056225675797
Stevenson, F.K.
ba803747-c0ac-409f-a9c2-b61fde009f8c
Rice, J., Ottensmeier, C.H. and Stevenson, F.K.
(2008)
DNA vaccines: precision tools for activating effective immunity against cancer.
Nature Reviews Cancer, 8 (2), .
(doi:10.1038/nrc2326).
Abstract
DNA vaccination has suddenly become a favoured strategy for inducing immunity. The molecular precision offered by gene-based vaccines, together with the facility to include additional genes to direct and amplify immunity, has always been attractive. However, the apparent failure to translate operational success in preclinical models to the clinic, for reasons that are now rather obvious, reduced initial enthusiasm. Recently, novel delivery systems, especially electroporation, have overcome this translational block. Here, we assess the development, current performance and potential of DNA vaccines for the treatment of cancer
This record has no associated files available for download.
More information
Published date: 2008
Keywords:
plasmid dna, immunity, phase-i, cancer, gene, protective immunity, minor histocompatibility antigens, development, genes, electroporation in-vivo, tumor-antigen, treatment, models, vaccine, b surface-antigen, time, dna, model, refractory prostate-cancer, cd8(+) t-cells, dendritic cells
Identifiers
Local EPrints ID: 62896
URI: http://eprints.soton.ac.uk/id/eprint/62896
ISSN: 1474-175X
PURE UUID: 876254f0-5a27-477a-8b85-03afe7b19b9e
Catalogue record
Date deposited: 12 Sep 2008
Last modified: 16 Mar 2024 02:54
Export record
Altmetrics
Contributors
Author:
J. Rice
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics
